阅读说明：本技术 一种促进吸收牛磺酸的组合物 (Composition for promoting absorption of taurine ) 是由 程刚 于 2020-05-27 设计创作，主要内容包括：本发明涉及一种促进牛磺酸吸收的组合物；具体是由牛磺酸与S-亚硝基谷胱甘肽组成。(The present invention relates to a composition for promoting the absorption of taurine; in particular to a taurine-nitrosoglutathione compound.)

1. A composition for promoting the absorption of taurine;

respectively crushing nitrosoglutathione and taurine, sieving with a 100-mesh sieve, mixing starch, 75% ethanol and dextrin in proportion to prepare a soft material, sieving with a 20-mesh sieve for granulation, drying at 45 ℃, sieving with a 20-mesh sieve for granulation, uniformly mixing fine powder and croscarmellose sodium, and tabletting.

Technical Field

The invention belongs to the field of medicines, and particularly relates to a composition for promoting taurine absorption.

Background

With the development of social economy and the change of life style of residents, chronic non-infectious diseases (chronic diseases for short) become a great public health problem affecting the health of China and even residents all over the world, and hypertension is one of the chronic diseases with high morbidity and is also the most important risk factor of cardiovascular and cerebrovascular diseases.

With the increase of age, the blood pressure of people is increased within a certain range, and the prevalence rate of hypertension is increased. According to the national health and nutrition survey results carried out in 1991 of the United states, the prevalence rate of hypertension in the group of 18-74 years is 20%, the prevalence rate of hypertension in the group of 50-59 years is 44%, the prevalence rate of hypertension in the group of 60-74 years is 67%, the rising rate is very obvious, and the group of 60 years is the high-incidence age group of hypertension.

Taurine is a sulfur-containing beta-amino acid, widely exists in human and mammal tissue cells, has important significance for maintaining normal physiological functions of human and animals, plays a role in protecting cells in the aspects of balancing cell osmotic pressure, maintaining cell membrane stability, regulating oxygen free radical damage, cell calcium homeostasis and the like, and the lack of taurine in vivo can cause various diseases.

Taurine is an osmotic pressure regulator, and can be used for increasing the amount of taurine transported into cells through membrane during hypertonic condition, increasing the outflow of taurine during hypotonic condition, regulating the osmotic pressure balance inside and outside cells, and preventing cell dehydration or edema. Taurine is also an endogenous Ca2+ homeostatic regulator in the body.

In studies of taurine deficiency and cardiomyopathy, taurine deficiency was found in cases of heart failure, and the results indicated that taurine deficiency decreased ventricular wall thickness and abnormal contraction and relaxation of the heart. Further studies have shown that taurine deficiency promotes changes in cardiac structure and function.

Currently, the trend in NO donor drug research is to combine NO donors with potent drugs using the prodrug principle to form 1 more potent new drug combination. The design mode of the medicine has the advantages of improving the bioavailability of the medicine, increasing the stability of the medicine, reducing toxic and side effects, promoting the long-acting of the medicine and the like.

The irreversibility of NO release remains a major obstacle for its application in the medical field, and there are many difficulties in drug design, especially in the treatment of physiological disorders caused by local depletion of endogenous NO. Dysfunction of NO synthesis has become a major factor in many cardiovascular diseases including hypertension, coronary artery disease and heart failure.

Disclosure of Invention

The present invention relates to a composition for promoting the absorption of taurine;

composition of taurine with S-nitrosoglutathione:

composition of taurine and sodium nitroprusside

Composition of taurine and prazosin

Composition of taurine with isoamyl nitrite:

drawings

FIG. 1: flow phase ratio screening

FIG. 2: HPLC profile of taurine

Detailed description of the preferred embodiment 1

Respectively crushing S-nitrosoglutathione and taurine, sieving with a 100-mesh sieve, mixing starch, 75% ethanol and dextrin in proportion to prepare a soft material, sieving with a 20-mesh sieve for granulation, drying at 45 ℃, sieving with a 20-mesh sieve for granulation, uniformly mixing the fine powder and the croscarmellose sodium, and tabletting.